Skip to content

uniQure QURE Total debt

Total debt at other companies

Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
$40.05M-22.3%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$395.09M+0.1%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$787.64M+259%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$9.11M-5.7%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$3.26B+32,101%
ALN
Alnylam PharmaceuticalsALNY
$263.69M-4.5%

Other financials

Income statement

See full
Revenue$3.6M+127%
Gross profit$3.3M+144%
Operating income-$45.7M-16.2%
Net income-$53.5M-22.7%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$140.0M-35.6%
Total equity$149.3M+343%
Total assets$778.7M+28.6%

Cash flow

See full
Operating cash flow-$38.2M+13.3%
CapEx$140.0K+11.1%
Free cash flow-$38.4M+13.2%

Valuation

See full
Market cap$3.09B+78.4%
Enterprise value$3.02B+124%
P/S170.9×+85.1×

Profitability

See full
Gross margin90.6%-2.9pp
Operating margin-1,059.7%+380pp
Net margin-1,154.4%+89.3pp
FCF margin-953.7%+169pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.4×-1.5×
Current ratio10.4×-1.6×

Where this comes from

Calculated from uniQure’s reported figures.

Plus components not separately reported this period.

The official record: uniQure’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about uniQure's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is uniQure's total debt?
uniQure (QURE) reported total debt of $63.32M in Q1 2026.
How has uniQure's total debt changed year-over-year?
uniQure's total debt decreased by 4.3% year-over-year, from $66.2M to $63.32M.
What is the long-term trend for uniQure's total debt?
Over 5 years (2020 to 2025), uniQure's total debt has grown at a -2.4% compound annual growth rate (CAGR), from $71.54M to $63.39M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.